Podcasts about transplantation

AJT January 2026 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Al-Faraaz Kassam to discuss the key articles of the January issue of the American Journal of Transplantation. Al-Faraaz Kassam is an Assistant Professor in Transplant Surgery at Johns Hopkins University [03:45] Evaluation of kidney procurement biopsy and machine perfusion on allograft outcomes: A retrospective cohort study of the OPTN database [11:23] Improving the  histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants [23:01] Exosome-primed T cell immunity is facilitated by complement activation [32:26] Landscape of subclinical rejection in a large international cohort of pediatric kidney transplant (kTx) recipients [42:19] Donor Heart Preservation at 10°C After Thoracoabdominal Normothermic Regional Perfusion Lowers Rates of Severe Primary Graft Dysfunction and Improves Recipient Transplant Outcomes  

Send us a textHair transplantation ~ Succeeding as a female in a Male-Dominated FieldMargaret Zakhary is a surgical PA, licensed in 9 US states. She has a family history of hair loss, with her Mum first experiencing hair loss at 16 years old, when she suffered permanent scarring from chemical damage. She tried wearing a wig for hair loss, but it looked terrible!Later on, when she was only 33, she became very ill, and Margaret, being just ten, began experiencing hair loss herself, and since has had several forms of hair loss throughout her life.She believes in turning tragedy into purpose, and shares how these events inspired her to study hair loss, to ensure that every patient has an advocate, and that they can get the care they need.Connect with Margaret:Instagram Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes. Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma who progressed on at least 1 prior line of therapy.1 A significant progression-free survival benefit was observed with the experimental combination compared with standard of care in this population. They also discussed data from cohort A of the phase 2 IFM2021-01 trial (NCT05572229), which evaluated subcutaneous teclistamab in combination with subcutaneous daratumumab in patients with newly diagnosed multiple myeloma. Results demonstrated that the combination was effective and safe in the frontline treatment of patients who were ineligible for transplant.2 The discussion also covered the broader treatment landscape, as the experts compared the use of bispecific antibodies with BCMA-directed CAR T-cell therapies. Frontline bispecific strategies for transplant-ineligible populations were also topics of conversation, as well as post-transplant consolidation with bispecifics. Ultimately, they stated that multiple myeloma care is undergoing a paradigm shift toward deeper minimal residual disease negativity, possible treatment de‑escalation, and even serious use of the word “cure” for the disease. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center, and Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both are also members of the ASTCT content committee. References Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6 Manier S, Lambert J, Marco M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood. 2025;146(suppl 1):367. doi:10.1182/blood-2025-367

Olivier Soubrane est un très grand chirurgien qui a pris le temps de venir nous parler de sa vie et dont la pudeur et l'humilité nous obligent. Passionné par son métier, Olivier Soubrane consacre sa vie à sauver les nôtres. Très impressionnée par cet homme, j'en ai oublié ma retenue légendaire (!!) et allez comprendre pourquoi, j'ai raconté ma vie... j'espère que vous ne m'en voudrez pas. Mais l'essentiel est ailleurs. Alors le gout de la médecine et cette envie de faire de la chirurgie, la différence entre les médecins d'hier et ceux d'aujourd'hui, mais aussi ce qui le rend le plus heureux et le plus fier ou encore sa relation aux patients, la réaction hospitalière lors du COVID et ses plus grands souvenirs de chirurgie, tout cela et bien plus encore c'est à découvrir dans cet épisode. Le dernier de l'année donc...Merci de votre fidélité et de votre soutien. A bientôtJuliaGénérique composé par Jean ThéveninHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

A heartfelt memoir about the search for religion and identity “I'm not Jewish.” For years, that's what David Weill told anyone who asked about his religious background. Yes, his father was a Jew who had left Nazi Germany as a boy. But his mother was a Southern Baptist. Growing up in New Orleans, religion wasn't something his family discussed, let alone practiced. As an adult, he developed a fervent zeal and profound devotion to his work as a specialist in organ transplants. Transplantation was all he needed to define and fulfill him—until a crisis shook him to the core. In 2015, after the simultaneous unraveling of his carefully crafted career and the death of his father, Weill began to doubt everything, including his purpose in life. While grappling with emotional pain and sinking deeper into despair, he began to suffer perplexing physical symptoms. In his moment of crisis, he was seized by a strong desire to practice a formal religion. But for Weill, the real question was, Which religion? Eventually, he chose Catholicism and was baptized at age fifty. He found solace in heart-to-heart talks with a priest and his daughters' happiness at having the whole family at church together. Everything was fine—until 2020, when he learned that his mother had converted to Judaism right before marrying his father. He was born a Jew. And in the eyes of the Jewish faith, he would always be Jewish. That realization sparked his second quest. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

This week we go back in time 2 years to review a recent paper from 2023 about outcomes of cardiac transplantation in the adult congenital heart patient (ACHD). Little has been written on this topic until this very robust and large scale report. How do single ventricle ACHD patients fair at transplant and how do they compare to non-ACHD heart transplant recipients? Why might 1 and 3 year outcomes not be a 'fair' method of assessing outcomes in this very high risk patient group? How do HLHS patient outcomes compare with other single ventricles? Are there better ways to measure risk in this patient group and how might the data in this work inform risk stratification and management of failing Fontan patients in whom transplantation is being considered? These are amongst the questions posed this week to the week's expert, Dr Daphne Hsu who is Professor of Pediatrics at the Albert Einstein College of Medicine at The Children's Hospital at Montefiore.https://doi.org/10.1016/j.jacc.2023.06.037For those interested in learning more about Dr. Hsu, take a listen to episode #166 from June, 2021:https://www.spreaker.com/episode/pediheart-podcast-166-a-conversation-with-professor-daphne-hsu--45144274

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.For a deeper dive, explore Dr. Cheng's many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.The discussion highlights:• How chronic GVHD independently contributes to immune deficits and infection susceptibility.• Infectious risks associated with FDA-approved therapies for chronic GVHD.• Common infections in this population and why vigilance matters.• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.

Att hantera jodkontrast för våra njursjuka patienter har länge varit en arbetsuppgift som krävt mycket tid och tankemöda. Men på sista tiden har förändringens vindar börjat blåsa, och möjligen ser vi ett paradigmskifte. Det kanske inte är så farligt att ge kontrast till patienter med njursvikt trots allt? Vad säger egentligen vetenskapen om korrelation och kausalitet? Vi intervjuar nefrologen Carin Wallquist som är på korståg mot fenomenet Renalism, och som ger oss en mycket ambitiös genomgång av kunskapsläget. Artiklar som nämns i avsnittet: McDonald JS, McDonald RJ. Risk of Acute Kidney Injury Following IV Iodinated Contrast Media Exposure: 2023 Update, From the AJR Special Series on Contrast Media. AJR Am J Roentgenol. 2024 Jul;223(1):e2330037. doi: 10.2214/AJR.23.30037. Epub 2024 Oct 4. PMID: 37791729. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol. 2008 Aug;191(2):376-82. doi: 10.2214/AJR.07.3280. PMID: 18647905. Chaudhury P, Armanyous S, Harb SC, Ferreira Provenzano L, Ashour T, Jolly SE, Arrigain S, Konig V, Schold JD, Navaneethan SD, Nally JV Jr, Nakhoul GN. Intra-Arterial versus Intravenous Contrast and Renal Injury in Chronic Kidney Disease: A Propensity-Matched Analysis. Nephron. 2019;141(1):31-40. doi: 10.1159/000494047. Epub 2018 Oct 26. PMID: 30368506. Choi B, Heo S, Mcdonald JS, Choi SH, Choi WM, Lee JB, Lee EA, Park SH, Seol S, Gan S, Park B, Choi HJ, Kim BJ, Rhee SY, Hong SB, Kim KH, Lee YH, Kim SS, Park RW. Risk of Contrast-Induced Acute Kidney Injury in Computed Tomography: A 16 Institutional Retrospective Cohort Study. Invest Radiol. 2025 Jun 1;60(6):376-386. doi: 10.1097/RLI.0000000000001141. Epub 2024 Nov 28. PMID: 39602881. Ehmann MR, Mitchell J, Levin S, Smith A, Menez S, Hinson JS, Klein EY. Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis. Intensive Care Med. 2023 Feb;49(2):205-215. doi: 10.1007/s00134-022-06966-w. Epub 2023 Jan 30. PMID: 36715705. Berglund F, Eilertz E, Nimmersjö F, Wolf A, Nordlander C, Palm F, Parenmark F, Westerbergh J, Liss P, Frithiof R. Acute and long-term renal effects after iodine contrast media-enhanced computerised tomography in the critically ill-a retrospective bi-centre cohort study. Eur Radiol. 2024 Mar;34(3):1736-1745. doi: 10.1007/s00330-023-10059-7. Epub 2023 Sep 2. PMID: 37658144; PMCID: PMC10873227. Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020 Mar;294(3):660-668. doi: 10.1148/radiol.2019192094. Epub 2020 Jan 21. PMID: 31961246. Chotkan KA, Hilbrands LB, Putter H, Konjin C, Schaefer B, Beenen LFM, Pol RA, Braat AE. Transplant Outcomes After Exposure of Deceased Kidney Donors to Contrast Medium. Transplantation. 2024 Jan 1;108(1):252-260. doi: 10.1097/TP.0000000000004745. Epub 2023 Sep 6. PMID: 37728569; PMCID: PMC10718213. Nijssen EC, Nelemans PJ, Rennenberg RJ, Theunissen RA, van Ommen V, Wildberger JE. Prophylaxis in High-Risk Patients With eGFR < 30 mL/min/1.73 m2: Get the Balance Right. Invest Radiol. 2019 Sep;54(9):580-588. doi: 10.1097/RLI.0000000000000570. PMID: 31033672. ===== Akutradiologikursens hemsida: www.akutradiologikursen.se Avsnittet presenteras i samarbete med Teleconsult. Läs mer om vad de kan erbjuda dig som radiolog, eller dig som chef på en underbemannad röntgenavdelning, på www.teleconsult.net !

Juliet Cruz and Maria Nikokavoura from the University of Ottawa interview Dr. Giovanni Ferrari for the TMM4950 Science Communication course about pushing the limits of donor heart preservation times. Dr. Ferrari is an associate professor of surgical sciences and the Scientific director of the cardiothoracic research program at Columbia University. Dr. Ferrari's research focuses on exploring how the heart functions and how we can better protect it, especially during surgery and organ transplantation. In this episode, Dr. Ferrari presents his findings from their work on a revolutionary method to keep donor hearts viable for up to 48 hours outside the body using a novel oxygen-rich cooling system. This could dramatically expand access to life-saving transplants and reshape how we think about organ preservation.Learn more: https://columbiasurgery.org/about/giovanni-ferrari-phd 0:00 | Introduction to podcast0:18 | Introduction to Dr. Ferrari1:11 | What sparked Dr. Ferrari's early interest in the heart and organ preservation?2:59 | What is the HOPE system, and how does it differ from standard cold storage?5:32 | Why push the limits of donor heart preservation, and what challenges came with it?6:44 | What surprising insights emerged from the RNA and metabolomic analyses?9:15 | How did it feel to see a HOPE-preserved heart beat again after 48 hours?11:15 | Can HOPE principles be applied to preserve other organs in transplantation?12:09 | What future research questions is the team most excited to pursue?14:30 | What advice does Dr. Ferrari have for young scientists bridging engineering and medicine?15:27 | Closing remarks“Only You with the Universe” by Spøq, licensed via Tribe of Noise PRO. All rights reserved. Listen more:https://prosearch.tribeofnoise.com/artists/show/78252/44118 Juliet Cruz and Maria Nikokavoura (Voice), Reena Corbane (Post-Production), Nika Abedian (Producer)

Einst war dies Science-fiction: die Idee, tierische Organe zu nutzen, um versagende Nieren, Herzen und Lebern beim Menschen zu ersetzen - die sogenannte Xenotransplantation. Heute jedoch wird das tatsächlich gemacht, mit wachsendem Erfolg. In der Schweiz und weltweit fehlen Spenderorgane. 2024 sind hierzulande 73 Personen gestorben, die auf eine Transplantation gewartet hatten; knapp 1300 Personen waren Ende letztes Jahr auf einer Warteliste für ein Spenderorgan. In dieser Situation gewinnt die Verpflanzung von tierischen Organen, die sogenannte Xenotransplantation, an Bedeutung: Tierorgane werden immer menschenähnlicher, und die Überlebenschancen von Transplantierten immer grösser. Dank Gentechnik könnte die Xenotransplantation mittelfristig eine echte Alternative zur menschlichen Organspende werden. Wie realistisch ist das? Wo steht diese Techinik heute, und: Wollen wir wirklich tierische Ersatzorgane in unserem Körper?

AJT December 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Hannah Bahakel to discuss the key articles of the December issue of the American Journal of Transplantation. Hannah Bahakel is a Clinical Immunodeficiency fellow at Cincinnati Children's Hospital Medical Center [03:34] Higher vs standard mean arterial pressure target in the immediate postoperative period of liver transplantation to prevent acute kidney injury: A randomized clinical trial (LIVER-PAM) [13:51] Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies [26:27] Tolerogenic lung allograft microenvironment suppresses pathogenic tissue remodeling following respiratory virus infection in mice [37:11] Therapeutic needs in solid organ transplant recipients: The American Society of Transplantation patient survey [48:19] Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Joseph Leventhal, Professor of Surgery and Director of Living Donor Kidney Transplantation at Northwestern University Feinberg School of Medicine. A pioneer in the field of organ transplantation, Dr. Leventhal's research is redefining what's possible in immune tolerance—an area often described as the “holy grail” of transplantation, where a patient's body can accept a donated organ without lifelong immunosuppressive drugs.Dr. Leventhal shares his journey from growing up in New York City to becoming one of the foremost leaders in transplant surgery and cell therapy innovation. He discusses how his team's groundbreaking clinical work has shown that tolerance can be achieved through cellular therapies, potentially freeing patients from the burdens of chronic immunosuppression.From the early days of cyclosporine to founding TRACT Therapeutics and developing first-in-human T-regulatory cell therapies, Joe reflects on the scientific curiosity, resilience, and collaboration that drive progress in a complex field. He also explores the evolving ecosystem for biotech innovation in Chicago, the challenges of translating academic research into clinical therapies, and the optimism surrounding the next generation of precision cell therapies.

In this episode, Prof. Fanny Mochel discusses the rationale and key findings from a retrospective cohort study of patients with CSF1R-related disorder treated with hematopoietic stem cell transplantation, highlighting the potential of this therapy to achieve both clinical and radiological disease stabilization. Journal CME is available until September 24, 2026 Read the article.

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

En France, plus de 90 000 personnes souffrent d'insuffisance rénale chronique terminale et ce nombre a considérablement augmenté ces dernières années. La transplantation rénale est l'option thérapeutique privilégiée pour les patients atteints d'IRCT, car elle offre des avantages substantiels en termes d'amélioration de l'espérance de vie et de la qualité de vie des patients. En France, seulement 4% des patients atteints d'IRCT reçoivent chaque année une transplantation rénale, tandis que la plupart d'entre eux restent en dialyse. 94% en hémodialyse et seulement 6% en dialyse péritonéale 1. Dans l'attente d'une greffe rénale, les patients sont donc amenés à dialyser. Mais quelle modalité choisir en pré-transplantation ? Pour répondre à cette question, nous avons aujourd'hui le privilège d'accueillir le docteur Séverine Baudreuil, néphrologue à l'hôpital Bicêtre. Référence : 1. Rapport REIN 2021   Invitée : Dr. Séverine Beaudreuil (Néphrologue, Le Kremlin-Bicêtre, APHP) Le Dr Beaudreuil déclare n'avoir aucun lien d'intérêt avec le sujet traité. L'équipe :
 Animation :  Pyramidale Communication Production : Pyramidale Communication Crédits : Pyramidale Communication, Sonacom   Ce podcast est uniquement destiné à des fins d'information. Si vous souhaitez contacter Baxter pour de plus amples informations ou pour signaler un événement indésirable, veuillez consulter notre site web à l'adresse suivante : https://www.baxter.fr/fr/contact-us   FR-RC00-240025 V1.0

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Christie Rampersad to discuss the key articles of the November issue of the American Journal of Transplantation. Christie Rampersad is clinical associate, in the Division of Nephrology at the University of Toronto in the Ajmera Transplant Centre [03:45] The early impacts of an attempt to standardize kidney procurement biopsy practices [13:40] The current state of simultaneous heart-liver transplantation in the United States [20:11] Engaging patients in organ transplant listing meetings: A survey study [37:32] Single-cell transcriptional landscape of liver transplant rejection reveals tissue persistence of clonally expanded, treatment-resistant T cells [45:32] Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant

Gastrointestinal complications are common—but often underrecognized—after lung transplantation. From diarrhea and nausea to malabsorption and poor appetite, these challenges can seriously impact recovery and long-term health outcomes.In this episode of the DNS Podcast, host Christina Rollins speaks with Bridget Doyle, MS, RD, LDN, CNSC, a transplant dietitian specializing in lung transplant nutrition. Bridget shares her expertise on identifying, managing, and supporting patients through complex GI issues post-transplant.Listeners will gain insights on:✅ The most frequent GI complications following lung transplant✅ How medications like immunosuppressants and antibiotics affect digestion✅ Practical nutrition strategies for diarrhea, nausea, and poor intake✅ Food safety guidance for immunocompromised patients✅ When to consider enteral or parenteral nutrition support✅ Key labs and nutrients to monitor for optimal recoveryTune in to hear evidence-based strategies for improving GI health and supporting successful long-term outcomes for transplant recipients. Visit us at dnsdpg.org to learn more.

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

Cool air and warm soils mean that it's a great time to divide and multiply the plants that you love, and Leslie and Marianne want to help you do it easily, efficiently, and with the least amount of plant pain as possible. What are they dividing in their gardens and how are they doing it? And why is it so good for the plants to rip them from happy homes just when they were thinking of taking a well-earned nap? For that matter, why aren't the girls sipping pumpkin lattes and waiting ‘till spring? Set down that bulb planter and grab those two forks, because it's all about FREE this week on The Garden Mixer. (Just for the record Marianne hates pumpkin lattes. Leslie's a fan.)___________________Be sure to hit the subscribe button so we can keep you smiling while you hit the mess [your garden] out there.Full Show Notes at⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠The Garden Mixer Podcast's Substack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠____________________Socials – Pick Your Platform:Follow us on Instagram⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@thegardenmixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indulge us on TikTok⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@the.garden.mixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spar with us on X⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@gardenmixerpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠“French Bistro” theme by Adieu Adieu. License D0LZBINY30GGTBBW

Première européenne: transplantation cardiaque partielle réussie chez un enfant Les brèves du jour Le bric à brac de Sapiens 5/5: un artiste nommé Sapiens "Vaccinez-moi" (2025) d'Alex Fredo pour parler des vaccins

It seems like every week, there's a new headline about some kind of sci-fi-esque organ transplant. Think eyeballs, 3D-printed kidneys, pig hearts.In her new book, Replaceable You: Adventures in Human Anatomy, science writer Mary Roach chronicles the effort to fabricate human body parts—and where that effort sometimes breaks down. Host Flora Lichtman speaks with Roach about everything from hair transplants to 3D-printed hearts, and why our anatomy is so hard to replicate in the first place.Guest: Mary Roach is a science writer and the author of Replaceable You: Adventures in Human Anatomy.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dans cet épisode, on lève le voile sur un sujet méconnu mais essentiel : le don de tissus humains. Caroline, coordonnatrice en prélèvement et développement, et Jimmy, spécialiste en tissus humains, nous expliquent comment ces dons peuvent transformer des vies, et pourquoi il est crucial d'en parler. Un échange éducatif, humain et sans filtre.  Nous vous rappelons que, si vous consentez au don de tissus, vous pouvez dès maintenant signer votre carte d'assurance maladie (RAMQ). L'autocollant à apposer sur la carte peut être commandé en ligne sur https://publications.msss.gouv.qc.ca/msss/document-000065/ ou encore, il vous sera remis lors du renouvellement de votre carte. Il est également essentiel d'en discuter avec vos proches afin de clarifier les volontés et décisions de chacun.  Le jeu de Carte Héma-Québec "La question qui tue pas" sera disponible, jusqu'à épuisement des stock, dans les Centres de dons Héma-Québec. 

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses. Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 

Return to Sport After Meniscal Allograft Transplantation in Collegiate and Professional Athletes Sachs JP, Mufti YN, Rubin J, et al. Am J Sports Med. 2025 Sep 3. doi:10.1177/03635465251366445 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

In a special co-branded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosing interleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses.  Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk. As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.

Spenderorgane sind rar und begehrt. Daher werden auch Tiere zu Organspendern. Noch ist die Xenotransplantation im Versuchsstadium. Doch das Forschungsfeld macht enorme Fortschritte. (00:32) Tierorgane werden immer menschlicher und die Überlebenschancen von Transplantierten immer grösser. Gentechnik macht es möglich, dass die Verpflanzung von tierischen Organen allmählich zu einer realistischen Alternative wird. Bereits schon ein halbes Jahr lebt ein Mensch, der eine Schweineniere erhalten hat. Vor kurzem wurde erstmals eine Schweinelunge in einen Menschen verpflanzt. Eine besonders komplizierte Transplantation. Jetzt versammeln sich Wissenschaftler:innen in Genf zur internationalen Xenotransplantations-Konferenz IXA (Irène Dietschi) (06:42) Meldungen: - Neue Neurblastom-Therapie aus Zürich - Erste Gentherapei gegen Chorea Huntington - Gigantische Felsenkunst in der Arabischen Wüste (Katharina Bochsler (15:37) Zwei Vulkane haben ein unterirdisches Verhältnis Anfang 2025 hat es auf Santorini tüchtig gerumpelt. Eine Reihe von Erdbeben bewegte die Inselgruppe in der südlichen Ägäis. Der Vulkan unterhalb des Kykladen-Archipels war spürbar unruhig geworden. Und nicht nur er, wie sich jetzt zeigt. Mitgewirkt hat auch der sieben Kilometer entfernte submarine Vulkan Kolumbos. Denn Forschende haben jetzt entdeckt: die beiden Vulkane teilen sich eine gemeinsame Magmakammer (Anita Vonmont) (21:16) Das Konzept der wasserreichen Exoplaneten verdampft Eine ETH-Studie widerlegt die Hypothese, wonach weit draussen im Kosmos von riesigen Ozeanen bedeckte - sogenannt hyzänische - Planeten kreisen. Dieses Konzept bewohnbarer Exoplaneten schürte in den letzten Jahren die Hoffnung, Leben im All zu finden. Forschende der ETH Zürich kommen nun zum Schluss: Diese «Wasserwelten» sind wohl nur Fiktion. In der Realität würde ein Grossteil des Wassers bald nach der Geburt der Planeten durch chemische Prozesse verschwinden. (Sandro Della Torre) LINKS Xenotransplantation IXA Konferenz: ixa2025.org Neuroblastom: nature.com/articles/s41586-025-09564-0 Gentherapie Chorea Huntington: uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii Planetary health Check: planetaryhealthcheck.org Kosmische Wasserwelten: iopscience.iop.org/article/10.3847/2041-8213/adff73

AJT October 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Christina Haugen to discuss the key articles of the October issue of the American Journal of Transplantation. Dr. Christina Haugen is an Assistant Professor of Surgery at the University of Cincinnati. [03:28] Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes—An analysis of COMPARE trial data [10:26] Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation [19:21] Potential targeting of urokinase-type plasminogen activator receptor–formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies [30:20] The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures [36:03] Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Hosts Roz and Dr. Sanchez-Fueyo discuss the key articles of the September issue of the American Journal of Transplantation. [03:30] Blunted cardiac reserve as a marker of cirrhotic cardiomyopathy—Cardiac outcomes following liver transplantation and comparison to the existing guidelines [14:18] Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial [25:55] Donor-derived cell-free DNA is associated with the degree of immunosuppression in lung transplantation [36:24] A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation [45:00] Cell therapy with human Interleukin 10–producing ILC2s enhances islet function and inhibits allograft rejection

In this episode, we are joined by Dr. Emile Bacha to discuss the emerging field of partial heart transplantation. The conversation explores the history of the concept, its reintroduction in recent years, and how techniques such as domino procedures are being developed to expand donor availability. Dr. Bacha explains the practical challenges of regulation, organ procurement, and immunosuppression, as well as early outcomes seen in paediatric patients. With reflections on valve durability, patient growth, and the future potential of this approach, this episode offers a detailed look into a promising area of congenital cardiac surgery and beyond.

In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002

Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna.   [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry

Dr. Chris Wiebe shares his expertise in use of HLA eplet mismatch load in estimating immunologic risk in transplantation. We cover considerations of de novo HLA-DSA formation, donor selection, impacts on post-transplant monitoring protocols, as well as immunosuppression.

This week we speak with congenital heart surgeon T. Konrad Rajab of Arkansas Children's Hospital about a recent report he co-authored on piglet experiments on partial heart transplantation. How did transplanted heart valves grow in comparison to standard homografts and how did the valvular function differ with time? Is there a minimum dose of immunosuppresion that can protect these valves and can this dose be lower than full heart transplantation immunosuppresion therapy? Is partial heart transplantation considered a potential life-long approach to valve replacement or mostly something used to allow for growth of valves during childhood? What do we know about the world's limited experience in humans of this approach? Dr. Rajab shares the answers this week in an exciting 'sci-fi' episode. The future is now.https://doi.org/10.1016/j.jacbts.2024.10.015